Evaluation of the Use of Cefoxitin in Combination in Continuous Parenteral Administration in the Treatment of Bone and Joint Infections
1 other identifier
observational
35
1 country
1
Brief Summary
Cephamycin related to 2nd generation cephalosporins, the use of cefoxitin has long been limited to antibiotic prophylaxis. Because of its spectrum (sensitive staphylococci, enterobacteria including ESBL, streptococci, anaerobes), its stability and its low cost, it could be useful in curative bone and joint infections, especially in case of infection polymicrobial disease in patients for whom antibiotic alternative per os is limited.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2018
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2018
CompletedFirst Submitted
Initial submission to the registry
February 19, 2019
CompletedFirst Posted
Study publicly available on registry
February 20, 2019
CompletedFebruary 22, 2019
February 1, 2019
2 months
February 19, 2019
February 20, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Rate of Treatment Failure
Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin
Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Secondary Outcomes (1)
Rate of use of this strategy
Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Study Arms (1)
bone and joint infection treated with cefoxitin
patients having had a bone or joint infection treated by cefoxitin in combination. Cefoxitin has been administered by continuous way, at home. A serum dosage of cefoxitin has been systematically achieved at equilibrium.
Interventions
the patients had cefoxitin in combination in continuous parenteral administration to treat their bone / joint infection
Eligibility Criteria
patients havind had a bon and joint infeciton treated with cefoxitin in combination in continuous parenteral administration managed at the Croix-Rousse Hospital
You may qualify if:
- patients havind had a bon and joint infeciton treated with cefoxitin in combination in continuous parenteral administration
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospices Civils de Lyon
Lyon, 69004, France
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Tristan Ferry, Md,PhD
Hospices Civils de Lyon
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- clinical research assistant
Study Record Dates
First Submitted
February 19, 2019
First Posted
February 20, 2019
Study Start
January 1, 2018
Primary Completion
March 1, 2018
Study Completion
April 1, 2018
Last Updated
February 22, 2019
Record last verified: 2019-02